Kiniksa Pharmaceuticals Income Tax Expense Over Time
| KNSA Stock | USD 22.08 0.24 1.08% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Kiniksa Pharmaceuticals Performance and Kiniksa Pharmaceuticals Correlation. Kiniksa |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share 5.415 | Quarterly Revenue Growth 0.674 | Return On Assets (0.03) |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Tax Expense Analysis
Compare Kiniksa Pharmaceuticals and related stocks such as Nuvalent, Ventyx Biosciences, and Arcellx Income Tax Expense Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NUVL | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | (2.3 M) | 521 K | (8.5 M) | (167.9 K) | (176.3 K) |
| VTYX | 146 K | 146 K | 146 K | 146 K | 146 K | 146 K | 146 K | 146 K | 146 K | 146 K | 358 K | (5.4 M) | (470 K) | (423 K) | (444.1 K) |
| ACLX | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | 422.7 K | (1 M) | (2.6 M) | 663 K | 696.1 K |
| CGEM | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 397 K | 397 K | (1.6 M) | (8.6 M) | (2.4 M) | 42.1 M | (14.1 M) | (13.4 M) |
| DAWN | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (2.3 M) | (10 M) | (9 M) | (8.6 M) |
| GPCR | 138 | 138 | 138 | 138 | 138 | 138 | 138 | 138 | 138 | 138 | 138 | 231 | 17 K | 236 K | 247.8 K |
| PHAT | 13 K | 13 K | 13 K | 13 K | 13 K | 13 K | 13 K | 13 K | 13 K | (45.4 M) | 4.2 M | 4.2 M | 25.3 M | 41.8 M | 43.9 M |
| REPL | 125 K | 125 K | 125 K | 125 K | 125 K | 125 K | 125 K | (2.1 M) | 451 K | 1.9 M | 2.4 M | 1.2 M | 288 K | 408 K | 643.2 K |
| NVCT | (24.0) | (24.0) | (24.0) | (24.0) | (24.0) | (24.0) | (24.0) | (24.0) | (24.0) | (24.0) | (24.0) | (4 K) | (298 K) | 1000 | 1.1 K |
| LYRA | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (213 K) | (82 K) | (1.1 M) | 13 K | 59 K | 62 K |
| KRON | (699 K) | (699 K) | (699 K) | (699 K) | (699 K) | (699 K) | (699 K) | (699 K) | (699 K) | (699 K) | (24.4 M) | (2 M) | (3.9 M) | 4.7 M | 5 M |
| GOSS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (5.4 M) | 2 M | 511 K | 8.2 M | 15.1 M | 10.8 M | 10 M | 5.7 M |
| COGT | (265 K) | (265 K) | (265 K) | (265 K) | (265 K) | (265 K) | (265 K) | (386 K) | 1.5 M | (1.6 M) | (8.4 M) | (467 K) | (7.6 M) | (6.8 M) | (6.5 M) |
| LRMR | (946 K) | (946 K) | (946 K) | (946 K) | (946 K) | (946 K) | (300 K) | (900 K) | (1.6 M) | (93.9 K) | (155 K) | (326 K) | (1.2 M) | (1.3 M) | (1.4 M) |
| KURA | 268.9 K | 268.9 K | 268.9 K | 268.9 K | 268.9 K | (20 K) | (31 K) | (30 K) | 3.4 M | (4.9 M) | (194 K) | (558 K) | 229 K | 206.1 K | 216.4 K |
| SPRO | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (7.7 M) | (363 K) | 1.1 M | (750 K) | (761 K) | 1.5 M | 1.6 M | 2.6 M | 2.7 M |
| BOLT | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | (482 K) | 11.5 M | 5.8 M | (2.2 M) | 1.7 M | 2.2 M |
| CHRS | 8.5 M | 8.5 M | 8.5 M | (7.1 M) | (15.4 M) | (7.4 M) | 656 K | 9.4 M | 4.7 M | 2.9 M | 3.5 M | 19.2 M | 34.9 M | (380 K) | (361 K) |
Kiniksa Pharmaceuticals and related stocks such as Nuvalent, Ventyx Biosciences, and Arcellx Income Tax Expense description
My Equities
My Current Equities and Potential Positions
| Kiniksa Pharmaceuticals | KNSA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Bermuda |
| Exchange | NASDAQ Exchange |
USD 22.08
Check out Kiniksa Pharmaceuticals Performance and Kiniksa Pharmaceuticals Correlation. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Kiniksa Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.